Reason for request

Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).

-


Clinical Benefit

Low

the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo.


Clinical Added Value

no clinical added value

VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V).


Contact Us

Évaluation des médicaments